ArticleJournal of hip preservation surgery2026
Heterotopic ossification prophylaxis after hip arthroscopy: a retrospective comparative study of acemetacin and indomethacin.
Article in Journal of hip preservation surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to compare the efficacy and safety profiles of acemetacin and indomethacin for prophylaxis of heterotopic ossification (HO) following hip arthroscopy. While indomethacin is a well-established agent, evidence on acemetacin remains limited. This retrospective study included 114 hips of 110 patients who underwent hip arthroscopy for femoroacetabular impingement between September 2022 and September 2024. Patients received indomethacin or acemetacin for 3 weeks postoperatively. HO development was assessed radiologically using the Brooker classification. Functional outcomes and non-steroidal anti-inflammatory drug-related adverse events were recorded and compared. HO developed in 6 hips (5.3%): 4 in the indomethacin group (8%) and 2 in the acemetacin group (3.1%) (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.